by Hanna | Apr 10, 2024 | Blog Post
The Federal Trade Commission (FTC) and Department of Justice (DOJ) have increasingly focused on the impact that mergers and acquisitions (M&A) in the life sciences could have on “nascent competition” – the competition that might eventually exist between...
by Hanna | Mar 27, 2024 | Blog Post
In its recent report “Not Again: Why the United States Can’t Afford to Lose its Biopharma Industry,” the Information Technology & Innovation Foundation (ITIF) highlights the important role of balanced competition policies in establishing and maintaining U.S....
by Hanna | Mar 11, 2024 | Blog Post
In recent years, the Federal Trade Commission (FTC) and Department of Justice (DOJ) have taken an increasingly aggressive approach towards life sciences mergers and acquisitions (M&A). This new approach not only represents a substantial pivot away from the...
by Hanna | Mar 7, 2024 | Blog Post
On February 29, PULSE partners from across the country met with policymakers on Capitol Hill to provide a real-world perspective on the critical role of pro-innovation mergers and acquisitions (M&A) and other collaborations in the life sciences industry. PULSE’s...
by Hanna | Feb 21, 2024 | Blog Post
In recent months, the Federal Trade Commission (FTC) and Department of Justice (DOJ) have pursued an increasingly aggressive new approach towards mergers and acquisitions (M&A). Taken together, the Agencies’ recently finalized Merger Guidelines and proposed...
by Hanna | Feb 13, 2024 | Blog Post
In a recent commentary for Law 360, biopharma expert Michael Kinch and economists Jee-Yonn Lehmann and Frederico Mantovanelli rightly point out that biopharmaceutical mergers and acquisitions (M&A) and other collaborations play an important role in promoting...
